Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Immunic (NASDAQ:IMUXGet Rating) in a research report report published on Monday, Stock Target Advisor reports. The firm currently has a $26.00 price target on the stock.

Several other research firms have also recently weighed in on IMUX. SVB Leerink dropped their price objective on Immunic from $45.00 to $9.00 and set an outperform rating for the company in a report on Friday, June 3rd. Wedbush dropped their price objective on Immunic from $61.00 to $14.00 in a report on Thursday, June 2nd. Finally, Aegis dropped their price objective on Immunic from $40.00 to $35.00 and set a buy rating for the company in a report on Monday, August 8th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $24.60.

Immunic Stock Performance

NASDAQ IMUX opened at $3.85 on Monday. Immunic has a fifty-two week low of $2.52 and a fifty-two week high of $14.50. The stock has a 50 day simple moving average of $4.39 and a two-hundred day simple moving average of $6.30. The stock has a market cap of $117.68 million, a P/E ratio of -1.27 and a beta of 1.98.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Altium Capital Management LP increased its position in Immunic by 890.0% during the 4th quarter. Altium Capital Management LP now owns 317,000 shares of the company’s stock valued at $3,034,000 after buying an additional 284,979 shares in the last quarter. Parkman Healthcare Partners LLC increased its position in Immunic by 11.8% during the 1st quarter. Parkman Healthcare Partners LLC now owns 1,089,251 shares of the company’s stock valued at $12,309,000 after buying an additional 115,068 shares in the last quarter. RTW Investments LP increased its position in Immunic by 57.7% during the 1st quarter. RTW Investments LP now owns 2,705,513 shares of the company’s stock valued at $30,572,000 after buying an additional 990,043 shares in the last quarter. Soleus Capital Management L.P. bought a new position in Immunic during the 4th quarter valued at approximately $1,675,000. Finally, MetLife Investment Management LLC bought a new position in Immunic during the 1st quarter valued at approximately $134,000. Institutional investors own 59.77% of the company’s stock.

About Immunic

(Get Rating)

Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

Read More

Analyst Recommendations for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.